The U.S. contraceptive market size is expected to reach USD 10 billion by 2027 registering a CAGR of 4.3%, according to a new report by Grand View Research, Inc. Improving access and awareness regarding Long-Acting Reversible Contraceptives (LARCs) and the effectiveness and convenience of using these products are expected to drive the growth of the market. The Guttmacher Institute reports 60% of women of reproductive age use contraception in the U.S. Use of hormonal contraceptives other than the birth control pill has significantly increased in married women.
Key market players are actively investing in the clinical pipeline, resulting in high competition and an increase in the quality of contraceptives. In January 2019, Mithra Pharmaceuticals announced the success of Estelle’s phase 3 study conducted in the U.S. and Canada, meeting the primary efficacy endpoint. The efficacy was reported to be similar to a recently FDA-approved Annovera & Lo-Loestrin. In August 2019, Agile Therapeutics, Inc. reported that the company is on track to request FDA approval for Twirla. The company is expected to conduct a review with the U.S. FDA’s advisory committee in October 2019 for Twirla’s New Drug Application.
Request a free sample copy or view report summary: U.S. Contraceptive Market Report
The prevalence of teenage pregnancies is highest in the U.S. Government initiatives, such as improving sex education and increasing access to contraceptives, is expected to boost the adoption of various birth control methods in the country
In 2019, the pills segment held the largest market share owing to the convenience of use and easy availability. The contraceptive pills market in the country is highly competitive due to the presence of generic products
Intrauterine Devices (IUDs) was also among the major product segments in 2019 and will expand further at a steady CAGR from 2020 to 2027 with increasing demand for hormonal IUDs
The rapid growth of subdermal implants in the U.S. contraceptive market is anticipated in the coming years. The subdermal implants market is highly consolidated with the presence of very few players
Key companies in this market are focusing more on M&A and product development to gain a competitive edge over others
In February 2020, TherapeuticsMD, Inc. entered into an agreement with Afaxys Pharma, LLC to increase access to ANNOVERA in the U.S. public health sector
In February 2020, Agile Therapeutics, Inc. received FDA approval for the sale of Twirla in the U.S.
Grand View Research has segmented the U.S. contraceptive market on the basis of the product:
U.S. Contraceptive Product Outlook (Revenue, USD Million, 2016 - 2027)
List of Key Players of the U.S. Contraceptive Market
Church & Dwight Co., Inc.
Reckitt Benckiser Group Plc
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
The Cooper Companies, Inc.
Mayer Laboratories, Inc.
Blairex Laboratories, Inc.
Pregna International Ltd.
Prosan International B.V.
SMB Corporation Of India
MELBEA Innovations Ltd.
This report has a service guarantee. We stand by our report quality.
Your transaction & personal information is safe and secure.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
Avail customized purchase options to meet your research needs:
"The quality of research they have done for us has been excellent..."